Viridian Therapeutics Inc (VRDN) - Financial and Strategic SWOT Analysis Review

Viridian Therapeutics Inc (VRDN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - Analyst’s summarization of the company’s business strategy.
• SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Viridian Therapeutics Inc (Viridian), formerly miRagen Therapeutics, focuses on the discovery and development of medicines for serious and rare diseases. The company’s major products in development are VRDN-001 and VRDN-003, which are aimed at treating thyroid eye disease (TED), and a portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, for autoimmune diseases. The company’s lead product candidate, VRDN-001, is an intravenous humanized monoclonal antibody targeting IGF-1R, and VRDN-003 is for subcutaneous administration, both aimed at treating thyroid eye disease (TED). The company develops novel RNA-based therapeutics, with a core focus on therapeutic antibodies and their roles in diseases. Viridian is headquartered in Waltham, Massachusetts, the US.

Viridian Therapeutics Inc Key Recent Developments

• Feb 26, 2026: Viridian Therapeutics Reports Recent Progress and 2025 Fourth Quarter and Full-Year Financial Results
• Jan 06, 2026: Viridian Therapeutics Prepares for Transformational 2026
• Jan 06, 2026: Viridian Therapeutics Prepares for 2026
• Dec 22, 2025: Viridian Therapeutics' BLA for Veligrotug Accepted and Granted Priority Review

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company